pyridostigmine has been researched along with physostigmine in 6 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 1 (16.67) | 18.7374 |
1990's | 2 (33.33) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 3 (50.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Bhatnagar, RK; Cannon, JG; Flynn, JR; Long, JP; Sahin, MF | 2 |
Chiang, PK; Doctor, BP; Gordon, RK; Leader, H; Padilla, FN; Payne, CS; Smejkal, RM | 1 |
Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
Brossi, A; Greig, NH; Holloway, HW; Lahiri, DK; Luo, W; Yu, QS | 1 |
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
1 review(s) available for pyridostigmine and physostigmine
Article | Year |
---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
5 other study(ies) available for pyridostigmine and physostigmine
Article | Year |
---|---|
Structure-activity studies on a potent antagonist to organophosphate-induced toxicity.
Topics: Animals; Cholinesterase Reactivators; Hemicholinium 3; Lethal Dose 50; Male; Mice; Paraoxon; Structure-Activity Relationship | 1991 |
Hemicholinium-3 congeners as potential antagonists to organophosphate-induced toxicity.
Topics: Animals; Chemical Phenomena; Chemistry; Cholinesterase Inhibitors; Dioxanes; Dioxins; Hemicholinium 3; In Vitro Techniques; Neuromuscular Junction; Oxazines; Paraoxon; Piperidines; Pyrrolidines; Rabbits; Synaptic Transmission | 1990 |
Binary antidotes for organophosphate poisoning: aprophen analogues that are both antimuscarinics and carbamates.
Topics: Animals; Antidotes; Carbamates; Chemical Phenomena; Chemistry; Cholinesterase Inhibitors; Guinea Pigs; In Vitro Techniques; Kinetics; Male; Organophosphate Poisoning; Parasympatholytics; Phenylpropionates; Rats; Rats, Inbred Strains | 1989 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Long-acting anticholinesterases for myasthenia gravis: synthesis and activities of quaternary phenylcarbamates of neostigmine, pyridostigmine and physostigmine.
Topics: Acetylcholinesterase; Animals; Butyrylcholinesterase; Cholinesterase Inhibitors; Humans; Mice; Myasthenia Gravis; Neostigmine; Phenylcarbamates; Physostigmine; Pyridostigmine Bromide | 2010 |